No Data
CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment
Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies Enter Late-Stage Development | DelveInsight
Insider Boost: CNS Pharmaceuticals Director Quietly Ramps Up His Stake
Insider Purchase: Director at $CNSP Buys 7,100 Shares
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress
CNS Pharmaceuticals Registers 9.79 Million Shares for Selling Holders
MNobody : But volume??
104175116 OP MNobody : let's see when market open